Literature DB >> 21194387

Adipokines and redox signaling: impact on fatty liver disease.

Maurizio Parola1, Fabio Marra.   

Abstract

Adipokines (adipose tissue cytokines) are polypeptide factors secreted by adipose tissue in a highly regulated manner. The 'classical' adipokines (leptin, adiponectin, and resistin) are expressed only by adipocytes, but other adipokines have been shown to be released by resident and infiltrating macrophages, as well as by components of the vascular stroma. Indeed, adipose tissue inflammation is known to be associated with a modification in the pattern of adipokine secretion. Several studies indicate that adipokines can interfere with hepatic injury associated with fatty infiltration, differentially modulating steatosis, inflammation, and fibrosis. Moreover, plasma levels of adipokines have been investigated in patients with nonalcoholic fatty liver disease in order to establish correlations with the underlying state of insulin resistance and with the type and severity of hepatic damage. In this Forum article, we provide a review of recent data that suggest a significant role for oxidative stress, reactive oxygen species, and redox signaling in mediating actions of adipokines that are relevant in the pathogenesis of nonalcoholic fatty liver disease, including hepatic insulin resistance, inflammation, and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21194387     DOI: 10.1089/ars.2010.3848

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  24 in total

Review 1.  Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2015-12       Impact factor: 1.894

2.  Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity.

Authors:  Suvarthi Das; Ashutosh Kumar; Ratanesh Kumar Seth; Erik J Tokar; Maria B Kadiiska; Michael P Waalkes; Ronald P Mason; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2013-02-22       Impact factor: 4.219

3.  Role of adiponectin in the metabolism of skeletal muscles in collagen VI-related myopathies.

Authors:  Tania Gamberi; Francesca Magherini; Michele Mannelli; Martina Chrisam; Matilde Cescon; Silvia Castagnaro; Alessandra Modesti; Paola Braghetta; Tania Fiaschi
Journal:  J Mol Med (Berl)       Date:  2019-03-29       Impact factor: 4.599

Review 4.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

5.  Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease.

Authors:  Chun Wang; Jianping Gong; Hao Wu
Journal:  Biomed Rep       Date:  2017-06-14

6.  The effects of metformin on simple obesity: a meta-analysis.

Authors:  Hong-Hong Ning; Jiong Le; Qian Wang; Charlotte Aimee Young; Bo Deng; Peng-Xiang Gao; Hai-Qiao Zhang; Shu-Lan Qin
Journal:  Endocrine       Date:  2018-08-27       Impact factor: 3.633

7.  Effects of endurance exercise training, metformin, and their combination on adipose tissue leptin and IL-10 secretion in OLETF rats.

Authors:  Nathan T Jenkins; Jaume Padilla; Arturo A Arce-Esquivel; David S Bayless; Jeffrey S Martin; Heather J Leidy; Frank W Booth; R Scott Rector; M Harold Laughlin
Journal:  J Appl Physiol (1985)       Date:  2012-09-27

Review 8.  Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease.

Authors:  Ariel E Feldstein; Shannon M Bailey
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

9.  Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis.

Authors:  Saurabh Chatterjee; Douglas Ganini; Erik J Tokar; Ashutosh Kumar; Suvarthi Das; Jean Corbett; Maria B Kadiiska; Michael P Waalkes; Anna Mae Diehl; Ronald P Mason
Journal:  J Hepatol       Date:  2012-12-01       Impact factor: 25.083

10.  Pathophysiology of NASH: perspectives for a targeted treatment.

Authors:  Fabio Marra; Sophie Lotersztajn
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.